World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
126
Citations
49981
World Ranking
2991
National Ranking
1656

Robert S. Benjamin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert S. Benjamin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 541 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert S. Benjamin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert S. Benjamin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 126 D-Index — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert S. Benjamin is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their work focuses predominantly within the field of Medicine, with particular contributions to subfields such as Pulmonary and Respiratory Medicine, Oncology, Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine, and Endocrinology, Diabetes and Metabolism.

Their research covers several main topics including:

  • Sarcoma Diagnosis and Treatment
  • Cardiac tumors and thrombi
  • Vascular Tumors and Angiosarcomas
  • Lymphoma Diagnosis and Treatment
  • Gastrointestinal Tumor Research and Treatment
  • CAR-T cell therapy research
  • Ear and Head Tumors

Robert S. Benjamin has contributed multiple papers to the scientific literature, including:

  • Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective, 2020, published in Advances in Experimental Medicine and Biology
  • Immuno-genomic landscape of osteosarcoma, 2020, published in Nature Communications
  • Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial, 2022, published in The Lancet Oncology
  • Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial, 2022, published in The Lancet Oncology
  • Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature, 2021, published in Cancer Medicine

Their frequent co-authors include Neeta Somaiah, Anthony P. Conley, Vinod Ravi, Dejka M. Araujo, and Ravin Ratan, all of whom have co-published more than 20 papers with Robert S. Benjamin.

Regarding publication venues, Robert S. Benjamin has contributed significantly to:

  • Journal of Clinical Oncology
  • Cancers
  • Clinical Cancer Research
  • Cancer
  • The Lancet Oncology

Best Publications

  • Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria

    Haesun Choi;Chuslip Charnsangavej;Silvana C. Faria;Homer A. Macapinlac

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

    M. S. Gordon;K. Margolin;M. Talpaz;G. W. Sledge

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

    Sewa S. Legha;Robert S. Benjamin;Bruce Mackay;Michael Ewer

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas

    Robert G. Maki;J. Kyle Wathen;Shreyaskumar R. Patel;Dennis A. Priebat

  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

    Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis

  • Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

    Margaret von Mehren;R. Lor Randall;Robert S. Benjamin;Sarah Boles

  • We Should Desist Using RECIST, at Least in GIST

    Robert S. Benjamin;Haesun Choi;Homer A. Macapinlac;Michael A. Burgess

  • Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients.

    Gunar K. Zagars;Matthew T. Ballo;Peter W. T. Pisters;Raphael E. Pollock M.D.

  • CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.

    Haesun Choi;Chuslip Charnsangavej;Silvana De Castro Faria;Eric P. Tamm

  • Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule

    Robert S. Benjamin;Peter H. Wiernik;Nicholas R. Bachur

  • Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial

    Omar Eton;Sewa S. Legha;Agop Y. Bedikian;Jiun-Kae Jack Lee

  • Treatment of uveal melanoma metastatic to the liver. A review of the M.D. Anderson Cancer Center experience and prognostic factors

    AY Bedikian;SS Legha;G Mavligit;CH Carrasco

  • A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

    Lei L. Chen;Jonathan C. Trent;Elsie F. Wu;Gregory N. Fuller

  • R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

    Alberto S. Pappo;Shreyaskumar R. Patel;John Crowley;Denise K. Reinke

  • Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

    Edward B. Rubenstein;Kenneth Rolston;Carmelita P Escalante;Ellen F Manzullo

  • An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

    M. Agulnik;J. L. Yarber;S. H. Okuno;M. von Mehren

  • Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

    Antonio C. Buzaid;Merrick I. Ross;Charles M. Balch;Seng-jaw Soong

Frequent Co-Authors

Shreyaskumar Patel
Shreyaskumar Patel The University of Texas MD Anderson Cancer Center
Raphael E. Pollock
Raphael E. Pollock The Ohio State University
Alexander J. Lazar
Alexander J. Lazar The University of Texas MD Anderson Cancer Center
Barry W. Feig
Barry W. Feig The University of Texas MD Anderson Cancer Center
Peter W.T. Pisters
Peter W.T. Pisters The University of Texas MD Anderson Cancer Center
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Sidney Wallace
Sidney Wallace The University of Texas MD Anderson Cancer Center
Gunar K. Zagars
Gunar K. Zagars The University of Texas MD Anderson Cancer Center
Robert G. Maki
Robert G. Maki University of Pennsylvania
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Medicine doesn’t always mean becoming a physician. There are diverse paths in healthcare that offer rewarding opportunities and can be accessed through flexible online programs.

For those interested in administrative roles, earning a healthcare administration degree online can open doors to leadership positions in hospitals, clinics, and other medical organizations. If working directly with medical records and insurance appeals to you, consider the best medical billing and coding schools online, many of which offer financial aid to help reduce costs.

Nursing continues to be in high demand, and different educational routes are available. Aspiring practical nurses may ask: do you have to take a teas test for lpn? Fortunately, some schools waive this requirement, making entry smoother. Already an RN with an associate’s degree? Numerous asn to fnp programs let you advance your career through convenient online bridge programs.

Exploring these related degrees can help you find a path that matches your interests, schedule, and goals in healthcare.

Best Scientists Citing Robert S. Benjamin

Trending Scientists

Recently Published Articles